EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual targeting of CDK4/6 and CDK7 augments tumor response and antitumor immunity in breast cancer models

Sungsoo Kim, Eugene Son, Ha-Ram Park, Minah Kim, Hee Won Yang

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci188839 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Sungsoo Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Cell Biology and. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Protein Kinase Inhibitors, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have transformed the treatment landscape for hormone receptor + (HR + ) breast cancer. However, their long-term efficacy is limited by acquired resistance, and CDK4/6i monotherapy remains ineffective in triple-negative breast cancer (TNBC). Here, we demonstrate that dual inhibition of CDK4/6 and CDK7 is a promising strategy to overcome therapeutic resistance in both HR + and TNBC models. Kinetic analyses revealed that CDK7 inhibitors (CDK7i) primarily impair RNA polymerase II–mediated transcription rather than directly targeting cell cycle CDKs. This transcriptional suppression attenuated E2F-driven transcriptional amplification, a key mechanism for developing CDK4/6i resistance following the degradation of the retinoblastoma protein. Consequently, combining CDK7i at minimal effective concentrations with CDK4/6i potently inhibited the growth of drug-resistant tumors. Furthermore, dual CDK4/6 and CDK7 inhibition stimulated immune-related signaling and cytokine production in cancer cells, promoting antitumor immune responses within the tumor microenvironment. These findings provide mechanistic insights into CDK inhibition and support the therapeutic potential of combining CDK7i with CDK4/6i for breast cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsTriple Negative Breast NeoplasmsCyclin-Dependent KinasesNeoplasm ProteinsBreast NeoplasmsHumansFemaleAnimalsCyclin-Dependent Kinase-Activating KinaseMiceCell Line, TumorXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Breast cancerCell biologyOncology

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase-Activating KinaseCDK4 protein, humanProtein Kinase InhibitorsCDK7 protein, humanCDK6 protein, humanCyclin-Dependent KinasesNeoplasm Proteins

Autor:innen und Institutionen

  • Department of Pathology and Cell Biology and.
  • Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • National Cancer Institute
  • National Institute of General Medical Sciences
  • American Cancer Society
  • V Foundation for Cancer Research
  • Melanoma Research Foundation

Zitieren

APA

Kim, S., Son, E., Park, H. R., Kim, M., & Yang, H. W. (2025). Dual targeting of CDK4/6 and CDK7 augments tumor response and antitumor immunity in breast cancer models. Journal of Clinical Investigation. https://doi.org/10.1172/jci188839

Vancouver

Kim S, Son E, Park HR, Kim M, Yang HW. Dual targeting of CDK4/6 and CDK7 augments tumor response and antitumor immunity in breast cancer models. Journal of Clinical Investigation. 2025. doi:10.1172/jci188839

BibTeX
@article{Kim2025,
  author = {Kim, Sungsoo and Son, Eugene and Park, Ha-Ram and Kim, Minah and Yang, Hee Won},
  title = {Dual targeting of CDK4/6 and CDK7 augments tumor response and antitumor immunity in breast cancer models},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci188839}
}
Kostenlos starten →